User login
Photo by Graham Colm
A new assay can overcome a limitation in blood biomarker research, according to a study published in Scientific Reports.
Researchers noted that transcriptome sequencing of whole-blood RNA holds promise for the identification and tracking of biomarkers.
Unfortunately, the high globin mRNA (gmRNA) content of erythrocytes can be problematic, causing technical bias and leaving biologically relevant molecules undetectable.
With this in mind, the researchers developed an assay known as GlobinLock, which is designed to preserve RNA quality by reducing globin content.
“The globin reduction rate of GlobinLock is sufficient for any application,” said study author Kaarel Krjutškov, PhD, of Karolinska Institutet in Huddinge, Sweden.
“It reduces the globin prevalence from 63% . . . to 5%, which makes it an effective tool for biotechnology companies as an additive to their kits.”
GlobinLock consists of a pair of gmRNA-specific oligonucleotides that silence the majority of globin RNA molecules by highly specific binding.
The oligonucleotides are introduced to a purified RNA sample and, according to the researchers, are effective immediately after RNA denaturation.
“We show that globin locking is fully effective not only for human samples but also for widely used animal models, like mouse and rat, cow, dog, and even zebrafish,” said study author Juha Kere, MD, PhD, of Karolinska Institutet.
Photo by Graham Colm
A new assay can overcome a limitation in blood biomarker research, according to a study published in Scientific Reports.
Researchers noted that transcriptome sequencing of whole-blood RNA holds promise for the identification and tracking of biomarkers.
Unfortunately, the high globin mRNA (gmRNA) content of erythrocytes can be problematic, causing technical bias and leaving biologically relevant molecules undetectable.
With this in mind, the researchers developed an assay known as GlobinLock, which is designed to preserve RNA quality by reducing globin content.
“The globin reduction rate of GlobinLock is sufficient for any application,” said study author Kaarel Krjutškov, PhD, of Karolinska Institutet in Huddinge, Sweden.
“It reduces the globin prevalence from 63% . . . to 5%, which makes it an effective tool for biotechnology companies as an additive to their kits.”
GlobinLock consists of a pair of gmRNA-specific oligonucleotides that silence the majority of globin RNA molecules by highly specific binding.
The oligonucleotides are introduced to a purified RNA sample and, according to the researchers, are effective immediately after RNA denaturation.
“We show that globin locking is fully effective not only for human samples but also for widely used animal models, like mouse and rat, cow, dog, and even zebrafish,” said study author Juha Kere, MD, PhD, of Karolinska Institutet.
Photo by Graham Colm
A new assay can overcome a limitation in blood biomarker research, according to a study published in Scientific Reports.
Researchers noted that transcriptome sequencing of whole-blood RNA holds promise for the identification and tracking of biomarkers.
Unfortunately, the high globin mRNA (gmRNA) content of erythrocytes can be problematic, causing technical bias and leaving biologically relevant molecules undetectable.
With this in mind, the researchers developed an assay known as GlobinLock, which is designed to preserve RNA quality by reducing globin content.
“The globin reduction rate of GlobinLock is sufficient for any application,” said study author Kaarel Krjutškov, PhD, of Karolinska Institutet in Huddinge, Sweden.
“It reduces the globin prevalence from 63% . . . to 5%, which makes it an effective tool for biotechnology companies as an additive to their kits.”
GlobinLock consists of a pair of gmRNA-specific oligonucleotides that silence the majority of globin RNA molecules by highly specific binding.
The oligonucleotides are introduced to a purified RNA sample and, according to the researchers, are effective immediately after RNA denaturation.
“We show that globin locking is fully effective not only for human samples but also for widely used animal models, like mouse and rat, cow, dog, and even zebrafish,” said study author Juha Kere, MD, PhD, of Karolinska Institutet.